Cargando…
Atypical hemolytic uremic syndrome and eculizumab therapy in children
Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating...
Autores principales: | Kim, Seong Heon, Kim, Hye Young, Kim, Su Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pediatric Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854840/ https://www.ncbi.nlm.nih.gov/pubmed/29563942 http://dx.doi.org/10.3345/kjp.2018.61.2.37 |
Ejemplares similares
-
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021) -
The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022) -
189 Eculizumab Therapy for Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Publicado: (2021)